Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

901 Walnut Street
4th Floor
Philadelphia, PA 19107

(215) 955 -7865
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. Myositis: Are autoantibodies pathogenic in necrotizing myopathy?
  2. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy
  3. Advances in the diagnosis, immunopathogenesis and therapies of igm-anti-mag antibody-mediated neuropathies
  4. Gene therapy for Duchenne muscular dystrophy: Balancing good science, marginal efficacy, high emotions and excessive cost
  5. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome
  6. Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors
  7. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome
  8. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
  9. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis
  10. Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations
  11. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business
  12. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  13. Close to the node but far enough
  14. Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?
  15. The spectrum of inflammatory myopathies: Dermatomyositis, polymyositis, necrotizing myositis, and inclusion-body myositis
  16. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
  17. Necrotising autoimmune myopathy (NAM): Antibodies seem to be specific markers in aiding diagnosis
  18. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
  19. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
  20. Efficacy of Intravenous Immunoglobulin in Neurological Diseases